Novartis’s pelacarsen has delivered the kind of result that forces investors to separate biological theory from clinical evidence: the cardiovascular outcomes trial showed no reduction in stroke, heart attack, cardiovascular deaths, or procedures to restore blood flow. For a drug aimed at one of the most closely watched cardiovascular risk factors, that is a direct challenge to the Lp(a) thesis.

The result does not merely weaken the case for one Novartis program. It may also prompt a broader reassessment of how investors value Lp(a)-targeting therapies, as well as other cardiovascular programs built around plausible disease mechanisms that have not yet translated into fewer major events.

According to reporting from The New York Times, pelacarsen failed to show a cardiovascular-outcomes benefit. The assignment’s central result is unusually clear: there were zero decreases in stroke, heart attack, cardiovascular deaths, or procedures intended to restore blood flow.

Why Lp(a) attracted attention

Lipoprotein(a), commonly abbreviated as Lp(a), has been widely viewed as a potential contributor to heart attacks and strokes. That belief helped establish a compelling development thesis: if elevated Lp(a) contributes to cardiovascular disease, then lowering it could potentially reduce major cardiovascular events.

Pelacarsen put that thesis to a demanding test. The relevant measure was not simply whether the drug affected a biomarker or addressed a recognized risk factor. The trial examined whether treatment translated into fewer serious outcomes. On the result supplied here, it did not.

That distinction matters for pharmaceutical valuation. A mechanism can be attractive, a biomarker can be well known, and a target can have a strong epidemiological rationale. But cardiovascular programs ultimately face an outcomes standard: fewer strokes, heart attacks, deaths, or interventions. Pelacarsen’s zero reductions leave investors with a much less certain connection between lowering or targeting Lp(a) and improving patient outcomes.

What the result means for Novartis

For Novartis, pelacarsen’s failure may increase scrutiny of its cardiovascular pipeline and the assumptions supporting cardiology-focused growth. The issue is not necessarily limited to one trial readout. Investor expectations surrounding Lp(a)-targeting therapies may now require more conservative framing, particularly where the investment case depends on the expectation that a measurable risk factor will produce a measurable decline in clinical events.

The result also raises a portfolio question. If a major outcomes trial aimed at Lp(a) did not reduce the specified cardiovascular events, investors may reassess how much future value to assign to related programs before their own outcomes data are available. That reassessment could remain selective: the result does not establish that every Lp(a)-targeting therapy will fail, nor does it resolve every question about patient selection, treatment timing, or trial design. It does, however, remove an important source of confidence from the broader thesis.

A wider warning for cardiovascular drug development

The pelacarsen disappointment was reported alongside disappointment for ziltivekimab, Novo Nordisk’s anti-inflammatory heart drug. These are distinct programs and distinct biological approaches, but their results arriving together could sharpen investor attention on cardiovascular development more broadly.

Inflammation-targeting programs may face a similar analytical test: does changing the underlying marker or pathway reduce actual cardiovascular events? The combined news may therefore encourage a broader review of Lp(a) and inflammation-focused programs, without supporting a blanket conclusion about either class or predicting future regulatory decisions.

For Novartis, the immediate analytical takeaway is straightforward. Pelacarsen’s trial did not validate the expected cardiovascular benefit across stroke, heart attack, cardiovascular death, or blood-flow-restoration procedures. Until stronger evidence emerges, investor expectations for Lp(a)-targeting therapies may need to reflect clinical uncertainty rather than relying primarily on the appeal of the target.